Longeveron LGVN 深 滬
等待開盤 10-17 09:30:00 美东时间
0.8103
-0.024
-2.84%
華盛通- 最 高0.89
- 今 開0.8327
- 成交量 50.31万股
- 最 低 0.8099
- 昨 收 0.834
- 總市值 1685.12万
- 52周最高 2.4843
- 市盈率 靜 --
- 換手率 2.42%
- 52周最低 0.633
- 委 比 -94.93%
- 總股本 2079.62万
- 歷史最高 450.00
- 量 比 0.89
- 振 幅 9.60%
- 歷史最低 0.633
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. is set to participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, where it will hold one-on-one meetings with investors. The company, which focuses on developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, is advancing Laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy with broad therapeutic potential. Longeveron...
10-06 13:15
Longeveron Appoints Dr. George Paletta to Board
Longeveron ( ($LGVN) ) just unveiled an announcement. On October 1, 2025, Longe...
10-02 04:47
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Longeveron Inc. announced the election of George Paletta, Jr., MD, MBA, to its Board of Directors. Dr. Paletta, a nationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in healthcare and business to the company. His expertise is expected to support Longeveron's stem cell therapy advancements targeting life-threatening conditions in children and the elderly. Longeveron is currently advancing multiple pipeline indica...
10-01 20:05
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Longeveron Inc. is participating in the Cell & Gene Meeting on the Mesa, where they will discuss strategic opportunities for their stem cell therapy in Alzheimer's disease. Their therapy, laromestrocel, has shown positive results in Phase 1 and Phase 2a clinical trials and has received FDA's RMAT and Fast Track designations. A successful Type B meeting with the FDA has provided a clear regulatory pathway for further development.
09-22 13:15
快讯 | Longeveron：已签订销售协议，将不时出售A类普通股股份，最高金额达1070万美元——SEC文件披露
Longeveron : Entered Into Sales Agreement for Sale of Shares of Class a Common ...
09-20 04:46
Longeveron Announces Leadership Changes Amidst CEO Departure
Longeveron ( ($LGVN) ) has issued an announcement. On August 27, 2025, Longever...
09-04 05:29
Longeveron appoints interim CEO
Longeveron (NASDAQ:LGVN) appointed Than Powell as interim chief executive officer, effective immediately. Powell replaces Wa’el Hashad. Company founder and chief science officer Joshua Hare was named ...
09-04 04:18
Longeveron Appoints Than Powell As Interim Chief Executive Officer, Effective Immediately; Dr. Joshua Hare Appointed As Executive Chairman Of The Board
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic
09-04 04:14
Longeveron® Announces Key Leadership Updates
Longeveron Inc. announced key leadership updates, appointing Than Powell as interim CEO and Dr. Joshua Hare as Executive Chairman of the Board. Wa’el Hashad will step down as CEO and Board member. The Company is conducting a national search for a permanent CEO. Longeveron is advancing its stem cell therapy pipeline, with laromestrocel currently in pivotal Phase 2b trials for HLHS, and plans to pursue additional indications including pediatric dil...
09-03 20:05
